Solid Tumor, Adult
294
91
122
74
Key Insights
Highlights
Success Rate
70% trial completion
Published Results
14 trials with published results (5%)
Research Maturity
74 completed trials (25% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.5%
31 terminated out of 294 trials
70.5%
-16.1% vs benchmark
0%
0 trials in Phase 3/4
19%
14 of 74 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 74 completed trials
Clinical Trials (294)
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors
Advanced or Recurrent Solid Tumors Treated With SHetA2
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
First-in-Human Study of ICT01 in Patients With Advanced Cancer
HMPL-A830 in Solid Tumors
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
First In Human Study of CX-2051 in Advanced Solid Tumors
Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca